Enhanced Drug Photosafety by Interchromophoric Interaction Due to Intramolecular Charge Separation

[EN] Imatinib is a synthetic tyrosinase inhibitor that is employed for the treatment of some kinds of human cancer. This drug has a low phototoxicity towards DNA, but its pyridylpyrimidine (1) fragment by itself exhibits significant phototoxicitiy. The intrinsic mechanism that leads to the enhanced photosafety of Imatinib is not yet known. Here, the properties of the excited state and interchromophoric interactions of Imatinib have been explored by using ultrafast laser flash photolysis and agarose electrophoresis studies. An intramolecular charge separation was directly observed for the irradiated Imatinib, which accounts for the relaxation of its excited state. An anionic form of pyridylpyrimidine (1) was deduced from the results of time-resolved resonance Raman spectra and by quenching experimental studies on compound 1 and diaminotoluene. In contrast, compound 1 efficiently transformed into triplet excited states with a long lifetime, which explained the phototoxicity associated with this fragment. This work provides insight into how to design drugs with lower phototoxicitiy or improved photostability by using interchromophoric interactions.This work was supported by Natural Science Foundation of China (21773151) and Shantou University Initial Funding (NTF16010). The Support from the Hong Kong Research Grants Council grants GRF 17307916, AoE/P-03/08, SEG HKU/07, The University of Hong Kong Development Fund 2013-2014 project "New Ultrafast Spectroscopy Experiments for Shared Facilities", the Spanish Government (CTQ2015-70164-P and BES-2013-066566) are also acknowledged.Li, M.; Yan, Z.; Zhu, R.; Phillips, DL.; Aparici-Espert, MI.; Lhiaubet, VL.; Miranda Alonso, MÁ. (2018). Enhanced Drug Photosafety by Interchromophoric Interaction Due to Intramolecular Charge Separation. Chemistry - A European Journal. 24(25):6654-6659. https://doi.org/10.1002/chem.201800716S665466592425Patel, S. (2013). Long-term efficacy of imatinib for treatment of metastatic GIST. Cancer Chemotherapy and Pharmacology, 72(2), 277-286. doi:10.1007/s00280-013-2135-8Lydon, N. (2009). Attacking cancer at its foundation. Nature Medicine, 15(10), 1153-1157. doi:10.1038/nm1009-1153Bucci, M., Goodman, C., & Sheppard, T. L. (2010). A decade of chemical biology. Nature Chemical Biology, 6(12), 847-854. doi:10.1038/nchembio.489Yang, J. C., Niu, D., Karsten, B. P., Lima, F., & Buchwald, S. L. (2016). Use of a «Catalytic» Cosolvent, N ,N -Dimethyl Octanamide, Allows the Flow Synthesis of Imatinib with no Solvent Switch. Angewandte Chemie International Edition, 55(7), 2531-2535. doi:10.1002/anie.201509922Yang, J. C., Niu, D., Karsten, B. P., Lima, F., & Buchwald, S. L. (2016). Use of a «Catalytic» Cosolvent, N ,N -Dimethyl Octanamide, Allows the Flow Synthesis of Imatinib with no Solvent Switch. Angewandte Chemie, 128(7), 2577-2581. doi:10.1002/ange.201509922Ōmura, S. (2016). A Splendid Gift from the Earth: The Origins and Impact of the Avermectins (Nobel Lecture). Angewandte Chemie International Edition, 55(35), 10190-10209. doi:10.1002/anie.201602164Ōmura, S. (2016). Ein vortreffliches Geschenk der Erde: Ursprünge und Auswirkungen der Avermectine (Nobel-Aufsatz). Angewandte Chemie, 128(35), 10344-10364. doi:10.1002/ange.201602164Korch, K. M., Eidamshaus, C., Behenna, D. C., Nam, S., Horne, D., & Stoltz, B. M. (2014). Enantioselective Synthesis of α-Secondary and α-Tertiary Piperazin-2-ones and Piperazines by Catalytic Asymmetric Allylic Alkylation. Angewandte Chemie International Edition, 54(1), 179-183. doi:10.1002/anie.201408609Korch, K. M., Eidamshaus, C., Behenna, D. C., Nam, S., Horne, D., & Stoltz, B. M. (2014). Enantioselective Synthesis of α-Secondary and α-Tertiary Piperazin-2-ones and Piperazines by Catalytic Asymmetric Allylic Alkylation. Angewandte Chemie, 127(1), 181-185. doi:10.1002/ange.201408609Lydon, N. B., & Druker, B. J. (2004). Lessons learned from the development of imatinib. Leukemia Research, 28, 29-38. doi:10.1016/j.leukres.2003.10.002AMITAY-LAISH, I., STEMMER, S. M., & LACOUTURE, M. E. (2011). Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatologic Therapy, 24(4), 386-395. doi:10.1111/j.1529-8019.2011.01431.xRousselot, P., Larghero, J., Raffoux, E., Calvo, F., Tulliez, M., Giraudier, S., & Rybojad, M. (2003). Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. British Journal of Haematology, 120(6), 1091-1092. doi:10.1046/j.1365-2141.2003.04208_3.xBrazzelli, V., Muzio, F., Manna, G., Moggio, E., Vassallo, C., Orlandi, E., … Borroni, G. (2011). Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate. Photodermatology, Photoimmunology & Photomedicine, 28(1), 2-5. doi:10.1111/j.1600-0781.2011.00621.xAtalay, F., Kızılkılıç, E., & Ada, R. S. (2013). Imatinib-Induced Psoriasis. Turkish Journal of Hematology, 30(2), 216-218. doi:10.4274/tjh.2012.0147Valeyrie, L., Bastuji-Garin, S., Revuz, J., Bachot, N., Wechsler, J., Berthaud, P., … Giraudier, S. (2003). Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients. Journal of the American Academy of Dermatology, 48(2), 201-206. doi:10.1067/mjd.2003.44Heidary, N., Naik, H., & Burgin, S. (2008). Chemotherapeutic agents and the skin: An update. Journal of the American Academy of Dermatology, 58(4), 545-570. doi:10.1016/j.jaad.2008.01.001Timmer-de Mik, L., Kardaun, S. H., Kramer, M. H. H., Hayes, D. P., & Bousema, M. T. (2009). Imatinib-induced pseudoporphyria. Clinical and Experimental Dermatology, 34(6), 705-707. doi:10.1111/j.1365-2230.2008.02985.xBaskaynak, G., Kreuzer, K.-A., Schwarz, M., Zuber, J., Audring, H., Riess, H., … Le Coutre, P. (2003). Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. European Journal of Haematology, 70(4), 231-234. doi:10.1034/j.1600-0609.2003.00044.xNardi, G., Lhiaubet-Vallet, V., & Miranda, M. A. (2014). Photosensitization by Imatinib. A Photochemical and Photobiological Study of the Drug and Its Substructures. Chemical Research in Toxicology, 27(11), 1990-1995. doi:10.1021/tx500328qDeria, P., Yu, J., Smith, T., & Balaraman, R. P. (2017). Ground-State versus Excited-State Interchromophoric Interaction: Topology Dependent Excimer Contribution in Metal–Organic Framework Photophysics. Journal of the American Chemical Society, 139(16), 5973-5983. doi:10.1021/jacs.7b02188Liu, B., Zhao, J., Luo, C., Lu, F., Tao, S., & Tong, Q. (2016). A novel bipolar phenanthroimidazole derivative host material for highly efficient green and orange-red phosphorescent OLEDs with low efficiency roll-off at high brightness. Journal of Materials Chemistry C, 4(10), 2003-2010. doi:10.1039/c5tc04393jFang, C., Frontiera, R. R., Tran, R., & Mathies, R. A. (2009). Mapping GFP structure evolution during proton transfer with femtosecond Raman spectroscopy. Nature, 462(7270), 200-204. doi:10.1038/nature08527Nicolaou, K. C. (2014). Advancing the Drug Discovery and Development Process. Angewandte Chemie International Edition, 53(35), 9128-9140. doi:10.1002/anie.201404761Nicolaou, K. C. (2014). Advancing the Drug Discovery and Development Process. Angewandte Chemie, 126(35), 9280-9292. doi:10.1002/ange.201404761Li, M.-D., Hanway, P. J., Albright, T. R., Winter, A. H., & Phillips, D. L. (2014). Direct Spectroscopic Observation of Closed-Shell Singlet, Open-Shell Singlet, and Triplet p-Biphenylyloxenium Ion. Journal of the American Chemical Society, 136(35), 12364-12370. doi:10.1021/ja505447qLi, M.-D., Albright, T. R., Hanway, P. J., Liu, M., Lan, X., Li, S., … Phillips, D. L. (2015). Direct Spectroscopic Detection and EPR Investigation of a Ground State Triplet Phenyl Oxenium Ion. Journal of the American Chemical Society, 137(32), 10391-10398. doi:10.1021/jacs.5b06302Du, L., Qiu, Y., Lan, X., Zhu, R., Phillips, D. L., Li, M.-D., … Winter, A. H. (2017). Direct Detection of the Open-Shell Singlet Phenyloxenium Ion: An Atom-Centered Diradical Reacts as an Electrophile. Journal of the American Chemical Society, 139(42), 15054-15059. doi:10.1021/jacs.7b07512Li, M.-D., Ma, J., Su, T., Liu, M., Yu, L., & Phillips, D. L. (2012). Direct Observation of Triplet State Mediated Decarboxylation of the Neutral and Anion Forms of Ketoprofen in Water-Rich, Acidic, and PBS Solutions. The Journal of Physical Chemistry B, 116(20), 5882-5887. doi:10.1021/jp301555eO’boyle, N. M., Tenderholt, A. L., & Langner, K. M. (2008). cclib: A library for package-independent computational chemistry algorithms. Journal of Computational Chemistry, 29(5), 839-845. doi:10.1002/jcc.20823Merrick, J. P., Moran, D., & Radom, L. (2007). An Evaluation of Harmonic Vibrational Frequency Scale Factors. The Journal of Physical Chemistry A, 111(45), 11683-11700. doi:10.1021/jp073974

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium

ABSTRACT Background Advanced-stage mycosis fungoides (MF)/Sezary syndrome (SS) patients are weighted by an unfavorable prognosis and share an unmet clinical need of effective treatments. International guidelines are available detailing treatment options for the different stages but without recommending treatments in any particular order due to lack of comparative trials. The aims of this second CLIC study were to retrospectively analyze the pattern of care worldwide for advanced-stage MF/SS patients, the distribution of treatments according to geographical areas (USA versus non-USA), and whether the heterogeneity of approaches has potential impact on survival. Patients and methods This study included 853 patients from 21 specialist centers (14 European, 4 USA, 1 each Australian, Brazilian, and Japanese). Results Heterogeneity of treatment approaches was found, with up to 24 different modalities or combinations used as first-line and 36% of patients receiving four or more treatments. Stage IIB disease was most frequently treated by total-skin-electron-beam radiotherapy, bexarotene and gemcitabine; erythrodermic and SS patients by extracorporeal photochemotherapy, and stage IVA2 by polychemotherapy. Significant differences were found between USA and non-USA centers, with bexarotene, photopheresis and histone deacetylase inhibitors most frequently prescribed for first-line treatment in USA while phototherapy, interferon, chlorambucil and gemcitabine in non-USA centers. These differences did not significantly impact on survival. However, when considering death and therapy change as competing risk events and the impact of first treatment line on both events, both monochemotherapy (SHR = 2.07) and polychemotherapy (SHR = 1.69) showed elevated relative risks. Conclusion This large multicenter retrospective study shows that there exist a large treatment heterogeneity in advanced MF/SS and differences between USA and non-USA centers but these were not related to survival, while our data reveal that chemotherapy as first treatment is associated with a higher risk of death and/or change of therapy and thus other therapeutic options should be preferable as first treatment approach

Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model

Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sézary syndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years. Clinical management is stage based; however, there is wide range of outcome within stages. Published prognostic studies in MF/SS have been single-center trials. Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers. PATIENTS AND METHODS: Literature review identified the following 10 candidate markers: stage, age, sex, cutaneous histologic features of folliculotropism, CD30 positivity, proliferation index, large-cell transformation, WBC/lymphocyte count, serum lactate dehydrogenase, and identical T-cell clone in blood and skin. Data were collected at specialist centers on patients diagnosed with advanced-stage MF/SS from 2007. Each parameter recorded at diagnosis was tested against overall survival (OS). RESULTS: Staging data on 1,275 patients with advanced MF/SS from 29 international sites were included for survival analysis. The median OS was 63 months, with 2- and 5-year survival rates of 77% and 52%, respectively. The median OS for patients with stage IIB disease was 68 months, but patients diagnosed with stage III disease had slightly improved survival compared with patients with stage IIB, although patients diagnosed with stage IV disease had significantly worse survival (48 months for stage IVA and 33 months for stage IVB). Of the 10 variables tested, four (stage IV, age > 60 years, large-cell transformation, and increased lactate dehydrogenase) were independent prognostic markers for a worse survival. Combining these four factors in a prognostic index model identified the following three risk groups across stages with significantly different 5-year survival rates: low risk (68%), intermediate risk (44%), and high risk (28%). CONCLUSION: To our knowledge, this study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic index, may be useful to stratify advanced-stage patients